Share information
251.70 €
+1.66 %
23/06/2026 17:35
+1.66 %
Open
High
Low
Volume
248.50 €
254.30 €
248.50 €
187,634
Latest News
17-Jun-2026
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
17-Jun-2026
UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline
05-Jun-2026
New EULAR 2026 data show CIMZIA[®] (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels
04-Jun-2026
EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus